Paclitaxel palmitate-loaded anti-HER2 cationic immunoemulsion: Pharmacokinetic and biodistribution study in healthy mice

D. Goldstein, S. Benita*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

The aim of this study was to evaluate the pharmacokinetic and biodistribution profile of paclitaxel palmitate (PCPL)-loadedanti-HER2 cationic immunoemulsion in healthy mice as compared to PCPL solution and PCPL-loaded cationic emulsion following intravenous (TV) injection. The observed density of the monoclonal antibody (MAb) conjugated to the cationic emulsion was found to be around 35 MAbs/droplet (70% coupling efficiency). Both PCPL-loaded cationic emulsion and immunoemulsion showed significant increases in tl/2, Cmax and AUC values as compared to the values of PCPL solution in mice. There was no significant difference in the t1/2 and C max values between PCPL-loaded cationic emulsion and PCPL-loaded immunoemulsion. However, the PCPL-loaded immunoemulsion concentrated much less in the liver and spleen than PCPL-loaded cationic emulsion. The pharmacokinetic behavior of the immunoemulsion was markedly different from the pharmacokinetic profile of the naked MAb showing that the MAb lost its intrinsic molecular pharmacokinetic properties following conjugation to the cationic emulsion.

Original languageEnglish
Pages (from-to)269-274
Number of pages6
JournalJournal of Drug Delivery Science and Technology
Volume19
Issue number4
DOIs
StatePublished - 2009

Keywords

  • Cationic emulsion
  • Immunoconjugates
  • Monoclonal antibodies
  • Paclitaxel palmitate
  • Pharmacokinetics

Fingerprint

Dive into the research topics of 'Paclitaxel palmitate-loaded anti-HER2 cationic immunoemulsion: Pharmacokinetic and biodistribution study in healthy mice'. Together they form a unique fingerprint.

Cite this